CG-598
/ CG Invites
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
February 02, 2021
Local Stabilization of Hypoxia-Inducible Factor-1α Controls Intestinal Inflammation via Enhanced Gut Barrier Function and Immune Regulation.
(PubMed, Front Immunol)
- "The effectiveness of CG-598 was comparable to other immunosuppressive therapeutics such as TNF-blockers or JAK inhibitors. These results suggest that CG-598 could be a promising therapeutic candidate to treat inflammatory bowel disease."
Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • CD4 • CD73 • CDH1 • HIF1A • IL10 • TFF3
August 05, 2019
Newly added product
(Korea Biomedical Review)
- Preclinical, IBD
Pipeline update
August 05, 2019
Crystal Genomics confirms efficacy of inflammatory bowel disease treatment
(Korea Biomedical Review)
- "Crystal Genomics said that it has confirmed the efficacy of CG-598, an inflammatory bowel disease (IBD) treatment candidate, through a pre-clinical trial. As a result of animal experiments on rats, the company observed the therapeutic effect of CG-598 in both the artificially created dinitrobenzene sulfonic acid-induced colitis model and dextran sulfate sodium-induced colitis model."
Preclinical
1 to 3
Of
3
Go to page
1